NTLA (STOCKS)
Intellia Therapeutics, Inc
$11.880200
-0.209800 (-1.74%)
Prev close: $12.090000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- John M. Leonard
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,859.30M
- Employees
- 598
- P/E (TTM)
- -3.60
- P/B (TTM)
- 2.33
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
9
Buy
8
Hold
2
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.80 | $-0.82 | +0.0152 | +1.86% |
|
Mar 2026 (Q1)
|
$-0.81 | $-0.93 | +0.1221 | +13.10% |
|
Dec 2025 (Q4)
|
$-0.83 | $-0.97 | +0.1439 | +14.78% |
|
Sep 2025 (Q3)
|
$-0.92 | $-1.02 | +0.1019 | +9.97% |
Financial Statements
| Revenues | $59.51M |
| Benefits Costs and Expenses | $475.76M |
| Costs And Expenses | $482.99M |
| Operating Expenses | $482.99M |
| Research and Development | $346.73M |
| Other Operating Expenses | $136.25M |
| Operating Income/Loss | -$423.48M |
| Income/Loss From Continuing Operations After Tax | -$399.98M |
| Income/Loss From Continuing Operations Before Tax | -$416.25M |
| Net Income/Loss | -$399.98M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$399.98M |
| Net Income/Loss Available To Common Stockholders, Basic | -$399.98M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.35 |
| Diluted Earnings Per Share | -$3.35 |
| Basic Average Shares | 364,693,000 |
| Diluted Average Shares | 364,693,000 |
| Assets | $857.16M |
| Current Assets | $527.83M |
| Noncurrent Assets | $329.33M |
| Fixed Assets | $15.06M |
| Other Non-current Assets | $314.27M |
| Liabilities | $129.46M |
| Current Liabilities | $79.39M |
| Accounts Payable | $11.71M |
| Wages | $14.42M |
| Other Current Liabilities | $53.25M |
| Noncurrent Liabilities | $50.07M |
| Equity | $727.71M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $727.71M |
| Liabilities And Equity | $857.16M |
| Net Cash Flow From Operating Activities | -$346.64M |
| Net Cash Flow From Operating Activities, Continuing | -$346.64M |
| Net Cash Flow From Investing Activities | -$48.47M |
| Net Cash Flow From Investing Activities, Continuing | -$48.47M |
| Net Cash Flow From Financing Activities | $346.52M |
| Net Cash Flow From Financing Activities, Continuing | $346.52M |
| Net Cash Flow | -$48.59M |
| Net Cash Flow, Continuing | -$48.59M |
| Comprehensive Income/Loss | -$400.39M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$401.66M |
| Other Comprehensive Income/Loss | -$208.37M |